Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).
Fernandez-Martinez A, Tanioka M, Ahn SG, Zagami P, Pascual T, Rediti M, Tang G, Hoadley KA, Venet D, Rashid NU, Spears PA, Di Cosimo S, de Azambuja E, Choudhury A, Rastogi P, Islam MN, Cortes J, Llombart-Cussac A, Swain SM, Sotiriou C, Prat A, Perou CM, Carey LA.
Fernandez-Martinez A, et al. Among authors: tang g.
Ann Oncol. 2024 Dec 18:S0923-7534(24)04989-5. doi: 10.1016/j.annonc.2024.12.010. Online ahead of print.
Ann Oncol. 2024.
PMID: 39706338
Free article.